Skip to content
Evigrade
MajorDirect oral anticoagulants (factor Xa inhibitors)×Non-steroidal anti-inflammatory drug, propionic acid derivative

Updated · Methodology

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, EMA). Non-selective non-steroidal anti-inflammatory drugs (NSAIDs), ketoprofen among them, inhibit prostaglandin synthesis and can therefore reduce platelet aggregation and prolong bleeding time (ketoprofen summary of product characteristics, SmPC). Ketoprofen can cause ulcers and bleeding in the stomach and gut. Epidemiological data suggest that its risk of serious gastrointestinal complications may be higher than with other NSAIDs, especially at high doses (ketoprofen SmPC). In clinical studies, NSAIDs given with edoxaban increased clinically relevant bleeding (edoxaban SmPC, European Medicines Agency, EMA). Among NSAIDs, pharmacokinetic data with edoxaban exist only for naproxen, which did not change edoxaban levels (edoxaban SmPC, EMA).

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Ketoprofen adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (ketoprofen SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The ketoprofen summary of product characteristics (SmPC) does not recommend ketoprofen with direct factor Xa inhibitors, edoxaban included. This advice does not depend on how long the drugs are taken (ketoprofen SmPC). The edoxaban SmPC also does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, EMA). If the combination cannot be avoided, monitor the patient strictly, both clinically and with laboratory tests (ketoprofen SmPC). Monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, FDA). Give ketoprofen at the lowest effective dose for the shortest time (ketoprofen SmPC). In older patients and in those with a previous ulcer, start ketoprofen at the lowest dose. Give gastroprotection (misoprostol or a proton pump inhibitor) to them and to patients taking other drugs that raise the risk of gastrointestinal complications (ketoprofen SmPC). Ketoprofen is contraindicated in moderate to severe renal impairment (ketoprofen SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Ketoprofen is contraindicated in active peptic ulcer and after previous gastrointestinal bleeding, ulcer or perforation (ketoprofen SmPC). Stop ketoprofen at once if gastrointestinal bleeding or an ulcer occurs (ketoprofen SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Ketoprofen